Forte Biosciences, Inc. financial data

Symbol
FBRX on Nasdaq
Industry
Pharmaceutical Preparations
Location
3060 Pegasus Park Drive, Building 6, Dallas, TX
State of incorporation
Delaware
Fiscal year end
December 31
Former names
Tocagen Inc (to 6/15/2020)
Latest financial report
10-Q - Q2 2024 - Aug 14, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 605 % -38.7%
Return On Equity -118 % -71.8%
Return On Assets -98.7 % -59.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 36.5M shares +0.61%
Common Stock, Shares, Outstanding 36.4M shares +73.1%
Entity Public Float 20.4M USD +16.6%
Common Stock, Value, Issued 36K USD +71.4%
Weighted Average Number of Shares Outstanding, Basic 21M shares +42.6%
Weighted Average Number of Shares Outstanding, Diluted 21M shares +42.6%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 17.2M USD +103%
Operating Income (Loss) -37.2M USD -53.5%
Net Income (Loss) Attributable to Parent -35.8M USD -49.5%
Earnings Per Share, Basic -0.69 USD/shares +40.5%
Earnings Per Share, Diluted -0.69 USD/shares +40.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 24.5M USD +19.9%
Assets, Current 25.7M USD -16.4%
Property, Plant and Equipment, Net 96K USD +220%
Other Assets, Noncurrent 271K USD -33.4%
Assets 26.1M USD -16.4%
Accounts Payable, Current 5.28M USD +75.5%
Accrued Liabilities, Current 3.84M USD +16.6%
Liabilities, Current 9.12M USD +44.7%
Accumulated Other Comprehensive Income (Loss), Net of Tax -7K USD -800%
Retained Earnings (Accumulated Deficit) -138M USD -34.8%
Stockholders' Equity Attributable to Parent 17M USD -31.8%
Liabilities and Equity 26.1M USD -16.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.67M USD -28.1%
Net Cash Provided by (Used in) Financing Activities -8K USD -233%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 36.4M shares +73.1%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.68M USD -28.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 24.5M USD +19.9%
Deferred Tax Assets, Valuation Allowance 18.6M USD +52.3%
Deferred Tax Assets, Gross 18.6M USD +52.3%
Depreciation 9K USD
Payments to Acquire Property, Plant, and Equipment 6K USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -35.8M USD -40.7%
Property, Plant and Equipment, Gross 124K USD
Deferred Tax Assets, Operating Loss Carryforwards 6.52M USD +7.88%
Share-based Payment Arrangement, Expense 3.16M USD -9.69%